No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Eight patients with clinically diagnosed mild to severe Alzheimer disease were treated during two six-week periods by a double-blind, single-crossover protocol with placebo or a combination of 18 gm of lecithin and 3 to 10 mg of oral physostigmine daily. No improvement in behavior, recent memory, or other neuropsychological functions occurred.
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010830:Physostigmine / Q000627:therapeutic use*; D014706:Verbal Learning / Q000187:drug effects
D010713:Phosphatidylcholines; D010830:Physostigmine